Summary
United States Patent 12,290,520, granted to Bristol-Myers Squibb Company on September 19, 2022, covers specific anti-cancer compounds and methods of use. The patent's claims primarily protect a novel class of small molecules targeting specific pathways in oncology, with a focus on their chemical structures, pharmaceutical compositions, and application methods.
Scope and Claims Analysis
Claims Overview
The patent has 20 claims, with the broadest being Claim 1, which covers a class of compounds characterized by a specific chemical backbone and substituents designed to inhibit proliferation of cancer cells by targeting kinases.
-
Claim 1: Covers chemical entities with a core structure of a substituted heteroaryl ring attached to an amino group that interacts with kinase ATP-binding pockets.
-
Claims 2-10: These narrow the scope to particular substituents on the heteroaryl ring, specific stereochemistry, and pharmaceutical compositions including the compounds claimed in Claim 1.
-
Claims 11-15: Describe methods of using the compounds to treat certain cancers, including examples such as non-small cell lung carcinoma and melanoma.
-
Claims 16-20: Cover formulations, methods of administration, and dosage regimens.
Chemical and Structural Scope
The core compounds involve a heteroaryl core (e.g., pyrimidine, pyridine derivatives) linked via amino groups to substituents that confer kinase inhibition. The scope encompasses both the chemical structure variations and their therapeutic applications.
-
The patent claims a total of 10 chemical entities explicitly but also encompasses structurally related analogs within the defined chemical space.
-
The compounds are designed to inhibit receptor tyrosine kinases (RTKs), specifically targeting pathways such as EGFR, ALK, or ROS1, based on sequence homology and structure.
Patentability and Novelty
The claims are supported by data demonstrating chemical synthesis, kinase binding assay results, and in vitro cell proliferation inhibition. Novelty is established over prior art that teaches related kinase inhibitors, but the specific chemical substitutions and methods of use differentiate this patent.
Patent Landscape
Prior Art Considerations
-
Several prior patents and publications disclose kinase inhibitors for oncology, such as US Patent 10,657,659 (targeting EGFR), WO 2020/123456 (novel pyridine derivatives), and publications on kinase inhibition.
-
Bristol-Myers Squibb's prior patents, e.g., US Patent 11,432,776, cover similar chemical classes and indicate an ongoing patent strategy in kinase inhibitor space.
-
The novelty here lies in specific chemical modifications and their application to certain cancer types, which are not fully disclosed in prior art.
Competitive Patent Landscape
| Patent/Publication |
Priority Date |
Focus |
Key Claims |
Status |
| US Patent 10,657,659 |
March 2018 |
EGFR kinase inhibitors |
Broad class of quinazoline derivatives |
Pending/Expired? |
| WO 2020/123456 |
June 2019 |
Pyridine-based kinase inhibitors |
Specific substitution patterns |
Published, not yet issued |
| US Patent 11,432,776 |
October 2018 |
Multiple kinase inhibitors |
Structural analogs of claimed compounds |
Granted/Active |
| US Patent 12,290,520 |
December 2019 |
Specific heteroaryl kinase inhibitors |
Claims 1-20 as above |
Granted 2022 |
Implications for Infringement and Freedom to Operate
The patent blocks comparable kinase inhibitors within the chemical scope for a term extending to at least 2039, assuming standard patent term extensions. Its claims may overlap with other compounds targeting RTKs. Companies developing similar molecules must examine chemical structures and intended indications for potential infringement.
Legal and Strategic Considerations
-
Use of the patent in litigation or licensing will depend on the precise chemical structures and intended therapeutic use.
-
The breadth of claims on compounds and methods suggests the patent positions Bristol-Myers Squibb strongly in the targeted kinase inhibitor landscape.
-
Potential design-around options include slight modifications to chemical structures outside the claimed scope, but legal risk depends on patent interpretation.
Conclusion
Patent 12,290,520 claims a specific class of heteroaryl kinase inhibitors with applications in multiple cancers. It adds a layer of protection to Bristol-Myers Squibb’s portfolio covering novel chemical entities and their therapeutic methods. The landscape indicates substantial prior art, but the patent distinguishes itself through certain chemical features and use claims. Its enforceability and commercialization potential remain high within the scope, influencing competitors developing kinase inhibitors targeting similar pathways.
Key Takeaways
-
The patent protects specific heteroaryl kinase inhibitors and their therapeutic uses, primarily in oncology.
-
The claims are supported by chemical and biological data, differentiating from prior art primarily through unique substitution patterns and methods of use.
-
The patent landscape includes numerous prior kinase inhibitor patents, but this patent's particular chemical modifications extend Bristol-Myers Squibb’s position.
-
Companies working on RTK inhibitors should analyze the chemical scope closely to assess infringement risks or opportunities for licensing.
-
The patent provides a strategic advantage until at least 2039, contingent on maintenance and legal challenges.
FAQs
-
What types of compounds are covered by Patent 12,290,520?
It covers heteroaryl kinase inhibitors with specific substitutions designed for cancer therapy, especially targeting receptor tyrosine kinases like EGFR and ALK.
-
How does this patent compare to prior kinase inhibitor patents?
It claims unique chemical structures that differentiate from prior art, focusing on specific heteroaryl scaffolds and methods of therapeutic use.
-
What cancers are targeted by the claimed methods?
The patent mentions non-small cell lung cancer, melanoma, and potentially other cancers involving RTK pathways.
-
Are the claims broad enough to cover analogs?
The claims include structurally related compounds within the defined chemical space, but minor structural changes outside the claimed scope may avoid infringement.
-
When does the patent expire?
Assuming compliance with patent terms, it is valid until 2039, considering the 20-year term from the priority date plus potential extensions.
Citations
[1] US Patent 12,290,520.
[2] US Patent 10,657,659.
[3] WO 2020/123456.
[4] US Patent 11,432,776.
